Vergent Bioscience

We’re pleased to welcome Paul Friel to the Vergent Bioscience Board of Directors. His experience will support Vergent as we continue to advance abenacianine and prepare for future growth. Learn more here: bit.ly/4sqKfnA

Phase 2B VISUALIZE study results published in @AnnSurgOncol demonstrate abenacianine with intraoperative molecular imaging improved tumor visualization during lung cancer surgery. bit.ly/4c6Md5v #OncologyInnovation #ClinicalResearch

Vergent Bioscience names Adam Gridley President & CEO. John Santini, PhD, moves to CTO to lead platform expansion as we advance a Phase 3 study evaluating abenacianine for tumor visualization during lung cancer surgery. Read more: bit.ly/43kDXu7 #Leadership

#News: Vergent Bioscience has initiated VISUALIZE 2, a Phase 3 pivotal study evaluating abenacianine (VGT-309) for tumor visualization during lung cancer surgery. Read more: bit.ly/4lB9aS0 #OncologyInnovation #ClinicalResearch

Following #ASCO25, CEO @JSantini1 spoke with ONCOLife to discuss how abenacianine (VGT-309) is shining a light on #lungcancersurgery. ▶️ Watch: bit.ly/44M9vJv #Innovation #OncologyInnovation #Biotech #ThoracicSurgery

#News: Phase 2B VISUALIZE study results will be presented by @PennMedicine’s Dr. Sunil Singhal at #ASCO25, demonstrating that intraoperative molecular imaging with abenacianine for injection (VGT-309) during lung surgery has the potential to improve surgical outcomes. More: bit.ly/439aILt

#News: @PennMedicine’s Dr. Sunil Singhal will present new data from Vergent Bioscience on abenacianine (VGT-309) at #ASCO25, showcasing advances in tumor visualization with the potential to transform how surgeons identify and remove cancerous tissue. bit.ly/4jQ326I

Our CEO @JSantini1recently chatted with @MedTechGurus about Vergent’s mission and efforts to help surgeons unlock the full potential of minimally invasive and robotic-assisted surgery by making tumors easier to see. Learn more: bit.ly/3Y6hZZK #LCAM #Innovation

We were honored to join the 5th International Sublobar Resections & Bronchoscopic Ablation Summit last week in Paris! Engaging with global experts who are advancing #LungCancer care through innovation inspires us to continue working toward better surgical outcomes. #InnovationInMedicine

#NEWS: Vergent has received Fast Track designation from the @US_FDA for our novel, investigational tumor-targeted fluorescent imaging agent. Read more: bit.ly/4j3ZEFm #meded #lungcancer

Vergent is a proud sponsor of the 5th International Sublobar Resections and Bronchoscopic Ablation Summit, taking place January 9 & 10 in #Paris. We’re looking forward to connecting with global leaders and exploring the latest in surgical #innovation.

#DYK when #lungcancer is caught early, surgery can be an effective treatment? Our mission is to make #cancer surgery more successful by enhancing #tumorvisualization during surgery. Learn more in this recent @MedTechGurus episode: bit.ly/3Y6hZZK #Innovation

Approximately every 2.5 minutes, someone in the U.S. is diagnosed with lung cancer. During #LungCancerAwarenessMonth, we join the community in raising awareness of #LungCancer as one of the most common and deadly cancers. Learn more about our work: vergentbio.com/technology

We’ve completed patient enrollment in our Phase 2 VISUALIZE trial evaluating the potential of our novel, investigational tumor-targeted fluorescent imaging agent to improve tumor visualization during lung cancer surgery. Learn more: vergentbio.com/news-2024-nov… #clinicaltrials

At @WMISWMIC next week, @PennMedicine’s Dr. Sunil Singhal will share clinical research that shows how enhanced tumor visualization may benefit surgeons and patients during #lungcancer surgery. Learn more here: bit.ly/4e1KZHw #WMIC2024 #tumorvisualization #meded #MedX

Phase 2 data published in @STS_CTsurgery journal @annalsthorsurg show VGT-309 may help surgeons see difficult-to-find and previously undetected tumors in real-time during #MIS and robotic-assisted surgery. bit.ly/4bNYCIE #TumorVisualization #LungCancer

CEO @JSantini1 spoke with ONCOLife about our investigational advanced imaging agent, VGT-309. See how we’re enhancing tumor visualization & creating the potential to make cancer surgery more successful for both surgeons & patients. healthandpharma.net/oncolife (p42) #MedEd #Biotech

We're excited to welcome Alix Alderman to our #leadership team! A renowned global regulatory professional, her more than 20 years of drug development experience will help drive our mission to reimagine tumor visualization. bit.ly/49VZnyp #BioTech #TeamVergent

Thanks to @9NewsMelb for highlighting our study of VGT-309 with @StVincentsMelb, as we aim to help surgeons see difficult-to-find tumors in real time during surgery. Check out the story below! #lungcancer #innovation @msanto92

New data presented at the 60th Annual Meeting of the Society of Thoracic Surgeons demonstrate that VGT-309 helps surgeons visualize primary and metastatic tumor tissue in the lung during surgery. Learn more: vergentbio.com/vergent-prese… #STS2024 @STS_CTsurgery #lungcancer